A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors

Trial Profile

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Andecaliximab (Primary) ; Bevacizumab; Carboplatin; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin; Paclitaxel; Pemetrexed
  • Indications Adenocarcinoma; Advanced breast cancer; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 05 Jun 2018 Results (n=44; data cutoff: 22 Sep 2017) assessing the effect of andecaliximab in combination with FOLFIRI and bevacizumab in patients with second line metastatic colorectal cancer, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2018 Results (n=15) assessing safety and tolerability of ADX with standard of care chemotherapy in patients with previously untreated metastatic breast cancer, were presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 24 Apr 2018 Results of Part A and the gastric/GEJ adenocarcinoma cohort of part B published in the Clinical cancer research: an official journal of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top